NorthWest Health Prop Real Est Inv Trust (TSE:NWH.UN) Reaches New 52-Week High – Still a Buy?

NorthWest Health Prop Real Est Inv Trust (TSE:NWH.UN) reached a new 52-week high on Monday . The stock traded as high as C$5.99 and last traded at C$5.98, with a volume of 227379 shares trading hands. The stock had previously closed at C$5.93.

Analyst Ratings Changes

A number of research firms have recently commented on NWH.UN. Royal Bank Of Canada set a C$5.50 target price on NorthWest Health Prop Real Est Inv Trust and gave the company a “sector perform” rating in a research report on Monday, November 24th. BMO Capital Markets upped their price target on shares of NorthWest Health Prop Real Est Inv Trust from C$5.00 to C$6.00 in a research note on Thursday, November 13th. Scotiabank increased their price objective on shares of NorthWest Health Prop Real Est Inv Trust from C$6.50 to C$7.00 in a research report on Thursday, November 13th. Finally, Canadian Imperial Bank of Commerce lifted their price objective on shares of NorthWest Health Prop Real Est Inv Trust from C$5.50 to C$5.75 in a research note on Thursday, November 13th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of C$6.00.

NorthWest Health Prop Real Est Inv Trust Stock Performance

The firm has a fifty day moving average price of C$5.50 and a 200 day moving average price of C$5.24. The company has a current ratio of 0.25, a quick ratio of 0.06 and a debt-to-equity ratio of 129.42. The firm has a market cap of C$1.50 billion, a PE ratio of 29.78, a price-to-earnings-growth ratio of 0.74 and a beta of 1.78.

About NorthWest Health Prop Real Est Inv Trust

Northwest Healthcare Properties Real Estate Investment Trust provides investors with access to a portfolio of high-quality healthcare real estate. The company provides investors exposure to a well-diversified portfolio of healthcare real estate located in the greater areas of cities such as Australasia, Brazil, Germany, and Canada of which Australasia derives a majority of revenue to the company.